Navigation Links
Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
Date:9/3/2007

GLASGOW, Scotland, Sept. 3 /PRNewswire/ -- Leading neurosurgical device developer Elekta will feature the newest advances in neurosurgical diagnostic and treatment devices, along with clinical workflow solutions that make neurosurgery more effective and efficient at the European Association of Neurosurgical Societies (EANS) European Congress September 2-7, 2007. More than 1,000 neurosurgeons and related medical professionals will gather at the Scottish Exhibition & Conference Centre in Glasgow for the event.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

Leksell Gamma Knife(R) Perfexion(TM) highlighted

Positioned at the entrance of the exhibition hall, Elekta will feature Leksell Gamma Knife(R) Perfexion(TM), a quantum leap in stereotactic radiosurgery. The revolutionary patented design of the new Leksell Gamma Knife Perfexion collimator system dramatically expands treatment reach, simplifying the process of treating multiple tumors in the same session. Leksell Gamma Knife Perfexion provides better dosimetry performance than any other competitive radiosurgical system currently on the market and is estimated to increase the number of patients that can benefit from Gamma Knife surgery by up to 40 percent.

In addition, Gamma Knife(R) surgery is a radiosurgical procedure that is specifically well suited for the treatment of brain metastases.

"Leksell Gamma Knife Perfexion offers brain metastasis treatment in less time than other radiosurgical devices. Feedback from the first users in France, the United Kingdom and the United States has been overwhelmingly positive. Professor Jean Regis, La Timone Hospital in Marseilles has published that it is possible to treat four brain metastases eccentrically located (frontal anterior, far lateral and posterior fossa) in less than two hours," says Rolf Kjellstrom, Vice President of Sales and Mark
'/>"/>

SOURCE Elekta
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. Innovation featured in NE Wisconsin Roundtable
3. Changes to U.S. patent law must nurture our culture of innovation
4. Who is minding the Innovation Gap?
5. Abbott vs. Thailand has implications for innovation and access
6. Visions: Benson touts embedded innovation
7. UW System must remove barriers to innovation
8. Fusion 2007: Innovation drives productivity in post 24x7 world
9. In western Wisconsin, the innovation economy is growing
10. Scott Converse, UW-Madison School of Business, on the innovation mind-set
11. Innovation expert speaks on the business-IT balancing act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
(Date:4/23/2014)... researcher has shed light on how an estimated one ... outback have become reviled as pests and culled on ... and Sustainability Institute at the University of Exeter,s Penryn ... from their historic role helping to create the country,s ... , The deserts of the Australian outback are a ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... Institute for Medical Research and a team of collaborators from ... for rheumatoid arthritis. The paper will be published in ... nature of the disease. The gene, dubbed REL, is a ... many roles in the body. The NF-B family seems to ...
... a new colon cancer screening technique created by Northwestern ... could potentially be as or more successful than a ... uses optical technology, called low-coherence enhanced backscattering (LEBS) spectroscopy, ... the rectum. Light shines on the tissue, scatters, and ...
... Techniques and instrumentation initially developed for ExoMars - Europe,s next ... to fly on a NASA mission in 2018, could also ... supply. A major study by the Imperial ... (STFC), aims to use this new technology as an inexpensive ...
Cached Biology News:Researchers identify new risk factor gene for rheumatoid arthritis 2Colon cancer screening technique shows continued promise in new study 2Mars mission could ease Earth's energy supply crisis 2
Prepared from plasminogen by activation with immobilized human uPA...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Biology Products: